Metabolism of the right ventricle and the response to hypertrophy and failure

Progress in Cardiovascular Diseases

Volumn 55, Issue 2, 2012, Pages 229-233

  Altin, S Elissa ^a   Schulze, P Christian ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Glycolysis; Heart failure; Oxidative Metabolism; Right ventricular failure

Indexed keywords

ADENOSINE TRIPHOSPHATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHODIESTERASE V; PROSTAGLANDIN D2; SOMATOMEDIN C;

ARTICLE; DOWN REGULATION; ENERGY CONSUMPTION; FATTY ACID METABOLISM; GLYCOLYSIS; HEART MUSCLE METABOLISM; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE OVERLOAD; HEART STRESS; HEART STROKE VOLUME; HUMAN; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATION KINETICS; PHYSIOLOGICAL PROCESS; PULMONARY HYPERTENSION;

BIOLOGICAL MARKERS; ENERGY METABOLISM; HEART FAILURE; HEART VENTRICLES; HUMANS; HYPERTROPHY, RIGHT VENTRICULAR;

EID: 84866610058     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2012.07.010     Document Type: Article

References (45)

1. Taegtmeyer H., Wilson C.R., Razeghi P., et al. Metabolic energetics and genetics in the heart. Ann N Y Acad Sci 2005, 1047:208-218.
2. Lopaschuk G.D., Belke D.D., Gamble J., et al. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994, 1213:263-276.
3. Bing R., Siegal A., Vitale A., et al. Metabolic studies on the human heart in vivo: part I and part II. Am J Med 1953, 15(284-296):504-515.
4. van der Vusse G.J., van Bilsen M., Glatz J.F. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res 2000, 45:279-293.
5. Kantor P.F., Lopaschuk G.D., Opie L.H. Myocardial energy metabolism. Heart physiology and pathophysiology 2001, 543-569. Academic Press, San Diego Calif. Fourth edition. N. Sperelakis, Y. Kurachi, A. Terzic, M.V. Cohen (Eds.).
6. Taegtmeyer H., Sen S., Vela D. Return to the fetal gene program. Anna N Y Acad Sci 2010, 1188:191-198.
7. Hue L., Taegtmeyer H. The Randle cycle revisited: a new head for an old hat. Am J Physiol Endocrinol Metab 2009, 297:578-591.
8. Randle P.J., Garland P.B., Hales C.N., et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785-789.
9. Abu-Erreish G.M., Neely J.R., Whitmer J.T., et al. Fatty acid oxidation by isolated perfused working hearts of aged rats. Am J Physiol 1977, 232:258-262.
10. McMillin J.B., Taffet G.E., Taegtmeyer H., et al. Mitochondrial metabolism and substrate competition in the aging Fischer rat heart. Cardiovasc Res 1993, 27:2222-2228.
11. Kates A.M., Herrero P., Dence C., et al. Impact of aging on substrate metabolism by the human heart. J Am Coll Cardiol 2003, 41:293-299.
12. Taegtmeyer H., Golfman L., Sharma S., et al. Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci 2004, 1015:202-213.
13. Dias C.A., Assad R.S., Caneo L.F., et al. Reversible pulmonary trunk banding, II: an experimental model for rapid pulmonary ventricular hypertrophy. J Thorac Cardiovasc Surg 2002, 124:999-1006.
14. Schwartz A., Lee K.S. Study of heart mitochondria and glycolytic metabolism in experimentally induced study of heart failure. Circ Res 1962, 10:321-332.
15. Barger P.M., Kelly D.P. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 2000, 10:238-245.
16. Sack M.N., Rader T.A., Park S., et al. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996, 94:2837-2842.
17. Karbowska J., Kochan Z., Smolenski R.T. Peroxisome proliferator-activated receptor alpha is downregulated in the failing human heart. Cell Mol Biol Lett 2003, 8:49-53.
18. Lee S., Doliba N., Osbakken M., et al. Improvement of myocardial mitochondrial function after hemodynamic support with left ventricular assist devices in patients with heart failure. J Thorac Cardiovasc Surg 1998, 116:344-349.
19. Shahzad K., Chokshi A., Schulze P.C. Supplementation of glutamine and omega-3 polyunsaturated fatty acids as a novel therapeutic intervention targeting metabolic dysfunction and exercise intolerance in patients with heart failure. Curr Clin Pharmacol 2011, 6:288-294.
20. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 2007, 356:1140-1151.
21. Voelkel N.F., Quaife R.A., Leinwand L.A., et al. Right ventricular function and failure: report of a National Heart, Lung and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006, 114:1883-1891.
22. Drake J.I., Bogaard H.J., Mizuno S., et al. Molecular signature of right heart failure program. Am J Resp Cell Mol Bio 2011, 45:1239-1247.
23. Zaffran S., Kelly R.G., Meilhac S.M., et al. Right ventricular myocardium derives from the anterior heart field. Circ Res 2004, 95:261-268.
24. Reddy S., Zhao M., Hu D.Q., et al. Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure. Physiol Genomics 2012, 44:562-575.
25. Kusachi S., Nishiyama O., Yasuhara K., et al. Right and left ventricular oxygen metabolism in open-chest dogs. Am J Physiol 1982, 243:761-766.
26. Kagaya Y., Kanno Y., Takeyama D., et al. Effects of long-term pressure overload on regional myocardial glucose and free fatty acid uptake in rats. A quantitative autoradiographic study. Circulation 1990, 81:1353-1361.
27. Takeyama D., Kagaya Y., Yamane Y., et al. Effects of chronic right ventricular pressure overload on myocardial glucose and free fatty acid metabolism in the conscious rat. Cardiovasc Res 1995, 29:763-767.
28. Nagaya N., Goto Y., Satoh T., et al. Impaired regional fatty acid uptake and systolic dysfunction in hypertrophied right ventricle. J Nucl Med 1998, 39:1676-1680.
29. Kim Y., Goto H., Kobayashi K., et al. Detection of impaired fatty acid metabolism in right ventricular hypertrophy: assessment by I-123 beta-methyl iodophenyl pentadecanoic acid (BMIPP) myocardial single-photon emission computed tomography. Ann Nucl Med 1997, 11:207-212.
30. Saito D., Tani H., Kusachi S., et al. Oxygen metabolism of the hypertrophic right ventricle in open chest dogs. Cardiovasc Res 1995, 25:731-739.
31. Vonknoordegraaf A., Galiè N. The role of the right ventricle in pulmonary arterial hypertension. Eur Respir Rev 2011, 20:243-253.
32. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
33. Ritchie M., Waggoner A.D., vila-Roman V.G., et al. Echocardiographic characterization of the improvement in right ventricular function in patients with severe pulmonary hypertension after single-lung transplantation. J Am Coll Cardiol 1993, 22:1170-1174.
34. Yonekura Y., Brill A.B., Som P., et al. Regional myocardial substrate uptake in hypertensive rats: a quantitative autoradiographic measurement. Science 1985, 227:1494-1496.
35. Bokhari S., Raina A., Rosenweig E.B., et al. PET imaging may provide a novel biomarker and understanding of right ventricular dysfunction in patients with idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging 2011, 4:641-647.
36. Can M.M., Kaymaz C., Tanboga I.H., et al. Increased right ventricular glucose metabolism in patients with pulmonary arterial hypertension. Clin Nucl Med 2011, 36:743-748.
37. Szczepaniak L.S., Dobbins R.L., Metzger G.J., et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 2003, 49:417-423.
38. Torriani M., Thomas B.J., Halpern E.F., et al. Intramyocellular lipid quantification: repeatability with 1H MR spectroscopy. Radiology 2005, 236:609-614.
39. O'Connor R.D., Xu J., Ewald G.A., et al. Intramyocardial triglyceride quantification by magnetic resonance spectroscopy: in vivo and ex vivo correlation in human subjects. Magn Reson Med 2011, 65:1234-1238.
40. Fang Y.H., Piao L., Hong Z., et al. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle. J Mol Med (Berl) 2012, 90:31-43.
41. Rastogi S., Sharov V.G., Mishra S., et al. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol 2008, 295:2149-2155.
42. Zhang L., Lu Y., Jiang H., et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol 2012, 59:913-922.
43. Phan T.T., Shivu G.N., Choudhury A., et al. Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope. Eur J Heart Fail 2009, 11:881-886.
44. Halbirk M., Nørrelund H., Møller N., et al. Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function. Am J Physiol Heart Circ Physiol 2010, 299:1220-1225.
45. Nikolaidis L.A., Mankad S., Sokos G.G., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965.